NewAmsterdam Pharma Company N.V. - NAMS Net Assets per Single Share

Graphic logo of NewAmsterdam Pharma (NAMS)

NewAmsterdam Pharma (NAMS) operates as a virtual pharmaceutical business, outsourcing the development and validation of metabolic agents to external partners under strict supervision. Profitability relies on exclusive patents in cholesterol therapy, which provides the company with significant pricing power. This daily price chart at the value of 5.33 complements data on the asset-light model, where drug production is fully entrusted to contract manufacturing organizations.

NewAmsterdam Pharma Company (NAMS): Share Book Value from 06/21/2023 to 10/28/2026

newamsterdampharma.com - analytical breakdowns and key metrics (NAMS)

- price and consensus price forecast:
Price Chart NewAmsterdam Pharma N.V.|NAMS - Consensus Target
- market capitalization data:
Market Value NewAmsterdam Pharma Company N.V.|NAMS - Company Buyout Price
- book capitalization data:
Net Assets per Single Share NewAmsterdam Pharma|NAMS - Net Asset Value|Market Capitalization to Book Value Ratio newamsterdampharma.com|NAMS - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital NewAmsterdam Pharma|NAMS - Long-Term Debt to Capital|Short-Term Debt to Equity NewAmsterdam Pharma Company N.V.|NAMS - Aggregate Debt Obligations|Debt to Book Capitalization Ratio NewAmsterdam Pharma Company N.V.|NAMS - Company Long-Term Liabilities|Company Short-Term Debts NewAmsterdam Pharma
Fundamental company valuation:NewAmsterdam Pharma N.V. - NAMS
Manufactured products of NewAmsterdam Pharma Company N.V.

Assessing the margin of safety for NewAmsterdam Pharma (NAMS), I am focusing on the issuer's capital base. This indicator measures the share of net assets attributable to a single common share. The current estimated book value per share is 5.33, reflecting the actual asset density. The trend in the estimated book value per share confirms the business's resilience. For a pharmaceutical company with an intellectual property model, this growth signifies the capitalization of innovative developments.

Competitors of NewAmsterdam Pharma (NAMS)

ASND: Net Assets per Single Share|MDGL: Accounting Value per Share|Corcept Therapeutics - Net Assets per Single Share|RYTM (rhythmtx.com) - Net Assets per Share|Net Assets per Single Share Akero AKRO|Share Book Value Metsera, Inc.|MoonLake Pharma (MLTX) - Book Value per Share|Accounting Value of a Share Crinetics Corp (CRNX)|Book Value per Share SLNO (Soleno Therapeutics)|amicusrx.com - Book Value per Share|Net Assets per Single Share 89bio (ETNB)|AGIO: Accounting Value of a Share|GPCR (Structure Pharma) - Net Assets per Single Share|MiMedx Corp (MDXG) - Accounting Value per Share|RZLT (Rezolute, Inc.) - Book Value per Share|Book Value per Share lexpharma.com (LXRX)|MBX Biosciences (MBX) - Accounting Value per Share|Accounting Value of a Share ALT (Altimmune Inc)|Aardvark Therapeutics Corp - Net Assets per Single Share|Accounting Value per Share Sagimet Biosciences Inc SGMT|BIOA (BioAge Labs, Inc.) - Book Value per Share|biomeafusion.com (BMEA) - Net Asset Value per Share|QNCX - Accounting Value per Share|Fractyl Health Inc. (GUTS) - Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share Pluri Inc. (PLUR)|Net Assets per Single Share SYBX (synlogictx.com)|LPCN: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS